世界の重症筋無力症治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Myasthenia Gravis Disease Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z3984 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、重症筋無力症治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬物治療、手術、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・重症筋無力症治療の市場動向 ・企業の競争状況、市場シェア ・重症筋無力症治療の種類別市場規模（薬物治療、手術、その他） ・重症筋無力症治療の用途別市場規模（病院、診療所、その他） ・重症筋無力症治療の北米市場規模2016-2027（アメリカ、カナダ） ・重症筋無力症治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・重症筋無力症治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・重症筋無力症治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・重症筋無力症治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（GlaxoSmithKline、Novartis、Teva Pharmaceutical、Roche、Bristol-Myers Squibb、Apotex、Cipla、Biogen、AbbVie、Bausch Health Companies Inc.、Sun Pharmaceuticals、Fresenius Kabi、Piramal Healthcare、RPG Life Sciences） ・結論

Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking.
The Americas accounted for the largest market share of the global myasthenia gravis disease market owing to the growing number of drug manufacturers, increasing awareness about the long-term effects of muscle dystrophy, and rising government funding for the treatment of this disease in the region. Moreover, the U.S. contributes to a significant market share in the global pharmaceutical industry.

Market Analysis and Insights: Global Myasthenia Gravis Disease Treatment Market
The global Myasthenia Gravis Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myasthenia Gravis Disease Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myasthenia Gravis Disease Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myasthenia Gravis Disease Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myasthenia Gravis Disease Treatment market.

Global Myasthenia Gravis Disease Treatment Scope and Market Size
Myasthenia Gravis Disease Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Myasthenia Gravis Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Medication
Surgery
Others

Segment by Application
Hospitals
Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
GlaxoSmithKline
Novartis
Teva Pharmaceutical
Roche
Bristol-Myers Squibb
Apotex
Cipla
Biogen
AbbVie
Roche
Bristol-Myers Squibb
Fresenius Kabi

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myasthenia Gravis Disease Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Medication
1.2.3 Surgery
1.2.4 Others
1.3 Market by Application
1.3.1 Global Myasthenia Gravis Disease Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Myasthenia Gravis Disease Treatment Market Perspective (2016-2027)
2.2 Myasthenia Gravis Disease Treatment Growth Trends by Regions
2.2.1 Myasthenia Gravis Disease Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Myasthenia Gravis Disease Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Myasthenia Gravis Disease Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Myasthenia Gravis Disease Treatment Industry Dynamic
2.3.1 Myasthenia Gravis Disease Treatment Market Trends
2.3.2 Myasthenia Gravis Disease Treatment Market Drivers
2.3.3 Myasthenia Gravis Disease Treatment Market Challenges
2.3.4 Myasthenia Gravis Disease Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Myasthenia Gravis Disease Treatment Players by Revenue
3.1.1 Global Top Myasthenia Gravis Disease Treatment Players by Revenue (2016-2021)
3.1.2 Global Myasthenia Gravis Disease Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Myasthenia Gravis Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Myasthenia Gravis Disease Treatment Revenue
3.4 Global Myasthenia Gravis Disease Treatment Market Concentration Ratio
3.4.1 Global Myasthenia Gravis Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myasthenia Gravis Disease Treatment Revenue in 2020
3.5 Myasthenia Gravis Disease Treatment Key Players Head office and Area Served
3.6 Key Players Myasthenia Gravis Disease Treatment Product Solution and Service
3.7 Date of Enter into Myasthenia Gravis Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Myasthenia Gravis Disease Treatment Breakdown Data by Type
4.1 Global Myasthenia Gravis Disease Treatment Historic Market Size by Type (2016-2021)
4.2 Global Myasthenia Gravis Disease Treatment Forecasted Market Size by Type (2022-2027)

5 Myasthenia Gravis Disease Treatment Breakdown Data by Application
5.1 Global Myasthenia Gravis Disease Treatment Historic Market Size by Application (2016-2021)
5.2 Global Myasthenia Gravis Disease Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Myasthenia Gravis Disease Treatment Market Size (2016-2027)
6.2 North America Myasthenia Gravis Disease Treatment Market Size by Type
6.2.1 North America Myasthenia Gravis Disease Treatment Market Size by Type (2016-2021)
6.2.2 North America Myasthenia Gravis Disease Treatment Market Size by Type (2022-2027)
6.2.3 North America Myasthenia Gravis Disease Treatment Market Size by Type (2016-2027)
6.3 North America Myasthenia Gravis Disease Treatment Market Size by Application
6.3.1 North America Myasthenia Gravis Disease Treatment Market Size by Application (2016-2021)
6.3.2 North America Myasthenia Gravis Disease Treatment Market Size by Application (2022-2027)
6.3.3 North America Myasthenia Gravis Disease Treatment Market Size by Application (2016-2027)
6.4 North America Myasthenia Gravis Disease Treatment Market Size by Country
6.4.1 North America Myasthenia Gravis Disease Treatment Market Size by Country (2016-2021)
6.4.2 North America Myasthenia Gravis Disease Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Myasthenia Gravis Disease Treatment Market Size (2016-2027)
7.2 Europe Myasthenia Gravis Disease Treatment Market Size by Type
7.2.1 Europe Myasthenia Gravis Disease Treatment Market Size by Type (2016-2021)
7.2.2 Europe Myasthenia Gravis Disease Treatment Market Size by Type (2022-2027)
7.2.3 Europe Myasthenia Gravis Disease Treatment Market Size by Type (2016-2027)
7.3 Europe Myasthenia Gravis Disease Treatment Market Size by Application
7.3.1 Europe Myasthenia Gravis Disease Treatment Market Size by Application (2016-2021)
7.3.2 Europe Myasthenia Gravis Disease Treatment Market Size by Application (2022-2027)
7.3.3 Europe Myasthenia Gravis Disease Treatment Market Size by Application (2016-2027)
7.4 Europe Myasthenia Gravis Disease Treatment Market Size by Country
7.4.1 Europe Myasthenia Gravis Disease Treatment Market Size by Country (2016-2021)
7.4.2 Europe Myasthenia Gravis Disease Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Myasthenia Gravis Disease Treatment Market Size (2016-2027)
8.2 Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Type
8.2.1 Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Application
8.3.1 Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Region
8.4.1 Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Myasthenia Gravis Disease Treatment Market Size (2016-2027)
9.2 Latin America Myasthenia Gravis Disease Treatment Market Size by Type
9.2.1 Latin America Myasthenia Gravis Disease Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Myasthenia Gravis Disease Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Myasthenia Gravis Disease Treatment Market Size by Type (2016-2027)
9.3 Latin America Myasthenia Gravis Disease Treatment Market Size by Application
9.3.1 Latin America Myasthenia Gravis Disease Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Myasthenia Gravis Disease Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Myasthenia Gravis Disease Treatment Market Size by Application (2016-2027)
9.4 Latin America Myasthenia Gravis Disease Treatment Market Size by Country
9.4.1 Latin America Myasthenia Gravis Disease Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Myasthenia Gravis Disease Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Myasthenia Gravis Disease Treatment Market Size (2016-2027)
10.2 Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Type
10.2.1 Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Application
10.3.1 Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Country
10.4.1 Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Myasthenia Gravis Disease Treatment Introduction
11.1.4 GlaxoSmithKline Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.1.5 GlaxoSmithKline Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Myasthenia Gravis Disease Treatment Introduction
11.2.4 Novartis Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 Teva Pharmaceutical
11.3.1 Teva Pharmaceutical Company Details
11.3.2 Teva Pharmaceutical Business Overview
11.3.3 Teva Pharmaceutical Myasthenia Gravis Disease Treatment Introduction
11.3.4 Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.3.5 Teva Pharmaceutical Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Myasthenia Gravis Disease Treatment Introduction
11.4.4 Roche Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.4.5 Roche Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Myasthenia Gravis Disease Treatment Introduction
11.5.4 Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Apotex
11.6.1 Apotex Company Details
11.6.2 Apotex Business Overview
11.6.3 Apotex Myasthenia Gravis Disease Treatment Introduction
11.6.4 Apotex Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.6.5 Apotex Recent Development
11.7 Cipla
11.7.1 Cipla Company Details
11.7.2 Cipla Business Overview
11.7.3 Cipla Myasthenia Gravis Disease Treatment Introduction
11.7.4 Cipla Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.7.5 Cipla Recent Development
11.8 Biogen
11.8.1 Biogen Company Details
11.8.2 Biogen Business Overview
11.8.3 Biogen Myasthenia Gravis Disease Treatment Introduction
11.8.4 Biogen Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.8.5 Biogen Recent Development
11.9 AbbVie
11.9.1 AbbVie Company Details
11.9.2 AbbVie Business Overview
11.9.3 AbbVie Myasthenia Gravis Disease Treatment Introduction
11.9.4 AbbVie Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.9.5 AbbVie Recent Development
11.10 Bausch Health Companies Inc.
11.10.1 Bausch Health Companies Inc. Company Details
11.10.2 Bausch Health Companies Inc. Business Overview
11.10.3 Bausch Health Companies Inc. Myasthenia Gravis Disease Treatment Introduction
11.10.4 Bausch Health Companies Inc. Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.10.5 Bausch Health Companies Inc. Recent Development
11.11 Sun Pharmaceuticals
11.11.1 Sun Pharmaceuticals Company Details
11.11.2 Sun Pharmaceuticals Business Overview
11.11.3 Sun Pharmaceuticals Myasthenia Gravis Disease Treatment Introduction
11.11.4 Sun Pharmaceuticals Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.11.5 Sun Pharmaceuticals Recent Development
11.12 Fresenius Kabi
11.12.1 Fresenius Kabi Company Details
11.12.2 Fresenius Kabi Business Overview
11.12.3 Fresenius Kabi Myasthenia Gravis Disease Treatment Introduction
11.12.4 Fresenius Kabi Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.12.5 Fresenius Kabi Recent Development
11.13 Piramal Healthcare
11.13.1 Piramal Healthcare Company Details
11.13.2 Piramal Healthcare Business Overview
11.13.3 Piramal Healthcare Myasthenia Gravis Disease Treatment Introduction
11.13.4 Piramal Healthcare Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.13.5 Piramal Healthcare Recent Development
11.14 RPG Life Sciences
11.14.1 RPG Life Sciences Company Details
11.14.2 RPG Life Sciences Business Overview
11.14.3 RPG Life Sciences Myasthenia Gravis Disease Treatment Introduction
11.14.4 RPG Life Sciences Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021)
11.14.5 RPG Life Sciences Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Myasthenia Gravis Disease Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Medication
Table 3. Key Players of Surgery
Table 4. Key Players of Others
Table 5. Global Myasthenia Gravis Disease Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Myasthenia Gravis Disease Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Myasthenia Gravis Disease Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Myasthenia Gravis Disease Treatment Market Share by Regions (2016-2021)
Table 9. Global Myasthenia Gravis Disease Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Myasthenia Gravis Disease Treatment Market Share by Regions (2022-2027)
Table 11. Myasthenia Gravis Disease Treatment Market Trends
Table 12. Myasthenia Gravis Disease Treatment Market Drivers
Table 13. Myasthenia Gravis Disease Treatment Market Challenges
Table 14. Myasthenia Gravis Disease Treatment Market Restraints
Table 15. Global Myasthenia Gravis Disease Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Myasthenia Gravis Disease Treatment Market Share by Players (2016-2021)
Table 17. Global Top Myasthenia Gravis Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis Disease Treatment as of 2020)
Table 18. Ranking of Global Top Myasthenia Gravis Disease Treatment Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Myasthenia Gravis Disease Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Myasthenia Gravis Disease Treatment Product Solution and Service
Table 22. Date of Enter into Myasthenia Gravis Disease Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Myasthenia Gravis Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Myasthenia Gravis Disease Treatment Revenue Market Share by Type (2016-2021)
Table 26. Global Myasthenia Gravis Disease Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Myasthenia Gravis Disease Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Myasthenia Gravis Disease Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Myasthenia Gravis Disease Treatment Revenue Market Share by Application (2016-2021)
Table 30. Global Myasthenia Gravis Disease Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Myasthenia Gravis Disease Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Myasthenia Gravis Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Myasthenia Gravis Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Myasthenia Gravis Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Myasthenia Gravis Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Myasthenia Gravis Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Myasthenia Gravis Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Myasthenia Gravis Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Myasthenia Gravis Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Myasthenia Gravis Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Myasthenia Gravis Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Myasthenia Gravis Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Myasthenia Gravis Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Myasthenia Gravis Disease Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Myasthenia Gravis Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Myasthenia Gravis Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Myasthenia Gravis Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Myasthenia Gravis Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Myasthenia Gravis Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Myasthenia Gravis Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Myasthenia Gravis Disease Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 62. GlaxoSmithKline Company Details
Table 63. GlaxoSmithKline Business Overview
Table 64. GlaxoSmithKline Myasthenia Gravis Disease Treatment Product
Table 65. GlaxoSmithKline Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 66. GlaxoSmithKline Recent Development
Table 67. Novartis Company Details
Table 68. Novartis Business Overview
Table 69. Novartis Myasthenia Gravis Disease Treatment Product
Table 70. Novartis Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 71. Novartis Recent Development
Table 72. Teva Pharmaceutical Company Details
Table 73. Teva Pharmaceutical Business Overview
Table 74. Teva Pharmaceutical Myasthenia Gravis Disease Treatment Product
Table 75. Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 76. Teva Pharmaceutical Recent Development
Table 77. Roche Company Details
Table 78. Roche Business Overview
Table 79. Roche Myasthenia Gravis Disease Treatment Product
Table 80. Roche Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 81. Roche Recent Development
Table 82. Bristol-Myers Squibb Company Details
Table 83. Bristol-Myers Squibb Business Overview
Table 84. Bristol-Myers Squibb Myasthenia Gravis Disease Treatment Product
Table 85. Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 86. Bristol-Myers Squibb Recent Development
Table 87. Apotex Company Details
Table 88. Apotex Business Overview
Table 89. Apotex Myasthenia Gravis Disease Treatment Product
Table 90. Apotex Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 91. Apotex Recent Development
Table 92. Cipla Company Details
Table 93. Cipla Business Overview
Table 94. Cipla Myasthenia Gravis Disease Treatment Product
Table 95. Cipla Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 96. Cipla Recent Development
Table 97. Biogen Company Details
Table 98. Biogen Business Overview
Table 99. Biogen Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 100. Biogen Recent Development
Table 101. AbbVie Company Details
Table 102. AbbVie Business Overview
Table 103. AbbVie Myasthenia Gravis Disease Treatment Product
Table 104. AbbVie Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 105. AbbVie Recent Development
Table 106. Bausch Health Companies Inc. Company Details
Table 107. Bausch Health Companies Inc. Business Overview
Table 108. Bausch Health Companies Inc. Myasthenia Gravis Disease Treatment Product
Table 109. Bausch Health Companies Inc. Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 110. Bausch Health Companies Inc. Recent Development
Table 111. Sun Pharmaceuticals Company Details
Table 112. Sun Pharmaceuticals Business Overview
Table 113. Sun Pharmaceuticals Myasthenia Gravis Disease Treatment Product
Table 114. Sun Pharmaceuticals Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 115. Sun Pharmaceuticals Recent Development
Table 116. Fresenius Kabi Company Details
Table 117. Fresenius Kabi Business Overview
Table 118. Fresenius Kabi Myasthenia Gravis Disease Treatment Product
Table 119. Fresenius Kabi Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 120. Fresenius Kabi Recent Development
Table 121. Piramal Healthcare Company Details
Table 122. Piramal Healthcare Business Overview
Table 123. Piramal Healthcare Myasthenia Gravis Disease Treatment Product
Table 124. Piramal Healthcare Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 125. Piramal Healthcare Recent Development
Table 126. RPG Life Sciences Company Details
Table 127. RPG Life Sciences Business Overview
Table 128. RPG Life Sciences Myasthenia Gravis Disease Treatment Product
Table 129. RPG Life Sciences Revenue in Myasthenia Gravis Disease Treatment Business (2016-2021) & (US$ Million)
Table 130. RPG Life Sciences Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myasthenia Gravis Disease Treatment Market Share by Type: 2020 VS 2027
Figure 2. Medication Features
Figure 3. Surgery Features
Figure 4. Others Features
Figure 5. Global Myasthenia Gravis Disease Treatment Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Myasthenia Gravis Disease Treatment Report Years Considered
Figure 10. Global Myasthenia Gravis Disease Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Myasthenia Gravis Disease Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Myasthenia Gravis Disease Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global Myasthenia Gravis Disease Treatment Market Share by Regions (2022-2027)
Figure 14. Global Myasthenia Gravis Disease Treatment Market Share by Players in 2020
Figure 15. Global Top Myasthenia Gravis Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis Disease Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Myasthenia Gravis Disease Treatment Revenue in 2020
Figure 17. Global Myasthenia Gravis Disease Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global Myasthenia Gravis Disease Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Myasthenia Gravis Disease Treatment Market Share by Type (2016-2027)
Figure 21. North America Myasthenia Gravis Disease Treatment Market Share by Application (2016-2027)
Figure 22. North America Myasthenia Gravis Disease Treatment Market Share by Country (2016-2027)
Figure 23. United States Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Myasthenia Gravis Disease Treatment Market Share by Type (2016-2027)
Figure 27. Europe Myasthenia Gravis Disease Treatment Market Share by Application (2016-2027)
Figure 28. Europe Myasthenia Gravis Disease Treatment Market Share by Country (2016-2027)
Figure 29. Germany Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Myasthenia Gravis Disease Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Myasthenia Gravis Disease Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Myasthenia Gravis Disease Treatment Market Share by Region (2016-2027)
Figure 39. China Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Myasthenia Gravis Disease Treatment Market Share by Type (2016-2027)
Figure 47. Latin America Myasthenia Gravis Disease Treatment Market Share by Application (2016-2027)
Figure 48. Latin America Myasthenia Gravis Disease Treatment Market Share by Country (2016-2027)
Figure 49. Mexico Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Myasthenia Gravis Disease Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Myasthenia Gravis Disease Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Myasthenia Gravis Disease Treatment Market Share by Country (2016-2027)
Figure 55. Turkey Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Myasthenia Gravis Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. GlaxoSmithKline Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 59. Novartis Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 60. Teva Pharmaceutical Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 61. Roche Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 62. Bristol-Myers Squibb Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 63. Apotex Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 64. Cipla Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 65. Biogen Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 66. AbbVie Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 67. Bausch Health Companies Inc. Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 68. Sun Pharmaceuticals Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 69. Fresenius Kabi Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 70. Piramal Healthcare Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 71. RPG Life Sciences Revenue Growth Rate in Myasthenia Gravis Disease Treatment Business (2016-2021)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed

---